Loratinib side effect management: how to deal with edema, peripheral neuropathy, and cognitive impairment
During the treatment of lorlatinib, special attention should be paid to side effects such as edema, peripheral neuropathy, and cognitive impairment. Effective control can be achieved through graded management, dosage adjustment, and targeted intervention. The following specific symptom identification and treatment strategies need to be adjusted in a timely manner based on clinical monitoring.
1. Edema management
Loratinib may cause peripheral or systemic edema, usually associated with changes in vascular permeability or cardiovascular effects. Mild edema can be relieved by adjusting body position, while moderate to severe cases require medical intervention.
(1) Symptom grading
Grade 1 is local asymptomatic edema; Level 2 impact on daily activities; Grade 3 with functional impairment; Level 4 life-threatening. Record the location, degree, and accompanying symptoms of edema.
(2) Handling measures
Medication should be temporarily suspended for levels 2 and above until recovery is ≤ level 1, and then reduced for recovery. Intractable edema requires evaluation of cardiovascular and renal function, and if necessary, diuretics should be used in combination or permanently discontinued.
2. Peripheral neuropathy
Manifested as numbness, stabbing pain, or abnormal sensation in the limbs, which may be related to drug neurotoxicity. Symptoms are often dose-dependent and require early identification and intervention.
(1) Monitoring points
Regularly assess neurological symptoms, including tactile, vibrational, and tendon reflexes. Patients with diabetes or chemotherapy history are at higher risk, and monitoring should be strengthened.
(2) Intervention strategy
Level 2 symptoms require suspension of medication and reduction after recovery; Consider permanent discontinuation of medication at levels 3-4. Symptomatic treatment can be achieved by combining vitamin B or analgesic drugs.
3 Cognitive Impairment
Including memory loss, decreased attention, etc., with a median occurrence time of 1.4 months. Most cases are reversible, but one should be cautious of serious mental symptoms such as suicidal tendencies.
(1) Risk assessment
Baseline screening of cognitive function and regular follow-up during treatment. Elderly or patients with a history of neurological disorders need to shorten the evaluation interval.
(2) Graded processing
Level 1 observable; Level 2 pause until reduced after recovery; Level 3-4 permanent discontinuation of medication. Avoid using other neurotoxic drugs in combination and refer to a psychiatric department if necessary.
Disclaimer：《Loratinib side effect management: how to deal with edema, peripheral neuropathy, and cognitive impairment》Edited and sorted by Seagull Pharmacy's editors. Please contact us in time if there is any infringement. In addition, the suggestions for drug usage, dosage and disease mentioned in the article are only for medical staff's reference, and can not be used as any basis for medication！